You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tyrosine kinase inhibitor (TKI)

Showing 1 - 25 of 9,784
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

Recruiting
  • Liver Neoplasms
  • Tislelizumab plus tyrosine kinase inhibitor
  • Beijing, Beijing, China
    302 Hospital
Sep 22, 2023

Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

Not yet recruiting
  • Stage IIIA Hepatocellular Carcinoma
  • Radiotherapy combined with TKI and Anti-PD-1 Antibody
  • (no location specified)
Sep 24, 2023

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

Diabetic Macular Edema Trial (EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph)

Not yet recruiting
  • Diabetic Macular Edema
  • (no location specified)
Oct 19, 2023

Condition Vasoregulation Function Endothelium in CML Getting TKI

Recruiting
  • Chronic Myeloid Leukaemia
  • taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
  • Moscow, Russian Federation
  • +1 more
Jan 11, 2023

CML (Chronic Myelogenous Leukemia Trial (KDS-1001)

Not yet recruiting
  • CML (Chronic Myelogenous Leukemia
  • (no location specified)
Jul 27, 2022

MSS, pMMR, Metastatic Colorectal Adenocarcinoma Trial in Shenyang (TKI ± anti-PD-1 antibody)

Recruiting
  • MSS
  • +2 more
  • TKI ± anti-PD-1 antibody
  • Shenyang, Liaoning, China
    Cancer Hospital of China Medical University/Liaoning Cancer Hosp
Sep 28, 2021

Nonproliferative Diabetic Retinopathy Trial (EYP-1901, Sham IVT)

Not yet recruiting
  • Nonproliferative Diabetic Retinopathy
  • (no location specified)
Aug 3, 2022

Metabolic Alternation and Clinicohematological Characteristic in

Not yet recruiting
  • CML, Chronic Phase
  • Tyrosine kinase inhibitor
  • (no location specified)
Nov 6, 2023

Outcomes of Tyrosine Kinase Inhibitor(TKI)Stopping in Chronic

Recruiting
  • Folate
  • +2 more
    • Nantong, China
      Affliated Hospital of Nantong University
    Dec 13, 2021

    HRQOL in Locally Advanced Thyroid Carcinoma

    Recruiting
    • Thyroid Cancer
    • +2 more
    • Tyrosine kinase inhibitor drugs.
    • Fuzhou, Fujian, China
      Road Fuma No.420
    Apr 11, 2023

    Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer Trial in Buffalo (dovitinib lactate,

    Completed
    • Adenocarcinoma of the Pancreas
    • +3 more
    • dovitinib lactate
    • +5 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Jul 20, 2022

    Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)

    Recruiting
    • Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
    • Topical Timolol
    • Hong Kong, Hong Kong
      Queen Mary Hospital
    Nov 14, 2023

    Renal Cell Carcinoma Trial in Worldwide (Nivolumab, Bempegaldesleukin, Axitinib)

    Active, not recruiting
    • Renal Cell Carcinoma
    • Nivolumab
    • +2 more
    • Springdale, Arkansas
    • +33 more
    Nov 22, 2022

    Graft Vs Host Disease, GVHD Trial in Tampa, Minneapolis (Pacritinib, Sirolimus, Tacrolimus)

    Active, not recruiting
    • Graft Vs Host Disease
    • GVHD
    • Tampa, Florida
    • +1 more
    Jul 27, 2022

    Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia Trial in Philadelphia (Text

    Recruiting
    • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • Chronic Phase Chronic Myelogenous Leukemia
    • Text Message-Based Navigation Intervention
    • Survey Administration
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Apr 7, 2022

    Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor Trial in Rotterdam

    Recruiting
    • Non Small Cell Lung Cancer
    • +2 more
      • Rotterdam, Netherlands
        Erasmus MC
      Feb 2, 2022

      Renal Cell Carcinoma Trial in Omaha, Cleveland, Philadelphia (Axitinib)

      Terminated
      Has Results
      • Renal Cell Carcinoma
      • Omaha, Nebraska
      • +2 more
      Jul 26, 2021

      Wet Age-related Macular Degeneration Trial in United States (Eyp-1901, Aflibercept 2Mg/0.05Ml Inj,Oph)

      Recruiting
      • Wet Age-related Macular Degeneration
      • Melbourne, Florida
      • +4 more
      Aug 18, 2022

      Thyroid Cancer, Thyroid Cancer, Medullary, Differentiated Thyroid Cancer Trial in Tampa (Lenvatinib, Sorafenib, Cabozantinib)

      Terminated
      Has Results
      • Thyroid Cancer
      • +5 more
      • Tampa, Florida
        H. Lee Moffitt Cancer Center and Research Institute
      Jul 12, 2021

      NSCLC Trial in Worldwide (Repotrectinib, Crizotinib)

      Not yet recruiting
      • Carcinoma, Non-Small-Cell Lung
      • Augusta, Georgia
      • +40 more
      Nov 29, 2023

      Diarrhea, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer Trial in Duarte (other, dietary supplement, drug)

      Active, not recruiting
      • Diarrhea
      • +2 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Duarte, California
        City of Hope Medical Center
      Jun 7, 2022

      Cancer, Cancer, Treatment-Related, Medication Adherence Trial in Chicago (Oncotool Intervention (symptom reporting + TKI

      Completed
      • Cancer
      • +4 more
      • Oncotool Intervention (symptom reporting + TKI education)
      • Oncotool Control (health information)
      • Chicago, Illinois
        Northwestern University
      Jan 25, 2023

      ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

      Completed
      Has Results
      • ALK-positive NSCLC
      • Sollentuna, Sweden
        Pfizer Innovations AB
      Mar 14, 2022

      TKI Discontinuation in CML Patients of China

      Recruiting
      • Leukemia
      • +4 more
        • Shenzhen, Guangdong, China
          Shenzhen Second People's Hospital
        Mar 15, 2022